The REACH framework for chemicals will contrary to the industry's
view, actually improve conditions for innovation in Europe,
according to EU Commissioner Erkki Liikanen.
Lilly pulls out the stops to put right non-compliance issues at its
sites in Indianapolis, evading a fine and raising the prospects for
the launch of two pipeline drugs.
The US FDA has advised manufacturers of drugs and dietary
supplements containing 30mg or more of iron per dose that they are
no longer required, by law, to use unit-dose packaging
The EU and US move a small step closer to a harmonised regulatory
system with the first-ever collaboration on the review of
scientific data in an application to start a clinical trial.
AstraZeneca is roundly rebuked by The Lancet in an editorial that
describes the firm's development of its new cholesterol-lowering
drug Crestor as a "triumph of marketing over science".
Mixed news on GMP compliance, as Australia's API has its
manufacturing license renewed after a six-week suspension and GSK
unveils a US FDA probe.
The UK High Court has issued injunctions against a number of
individuals found to be involved in the harassment of staff working
for UK-based Japanese pharmaceutical companies.
European groups involved in developing and supplying reference
materials for chemical analysis have reached agreement on the new
Aventis has had its knuckles rapped by the European Union - and
€99m fine - for its alleged involvement in a cartel to control the
price of sorbates.
The US FDA's task force on counterfeiting of drugs issued its
preliminary report on schedule at the end of last week, and said
that it would be preparing a final document for early in 2004.
The European Union Council of Ministers has agreed a 'Common
Position' aimed at improving the regulatory framework for human
medicines in Europe.
France has announced a series of measures aimed at boosting the
country's R&D capabilities, including an increase in the
national research budget and extra funding for scientists.
BASF has started work on a combined heat and power plant at its
site in Ludwigshafen that will help the company meet its long-term
The UK MHRA admits to delays in the processing of marketing
applications because of a huge number of files submitted ahead of
new EU legislation.
The government of Germany has had its controversial health reform
policy voted in by the country's parliament with a comprehensive